Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden administration’s drug-price cuts.